Gene therapies are redefining medicine.

From CAR-T in oncology to in vivo gene editing, we are entering an era where one-time treatments can potentially cure diseases once considered untreatable. Across Europe, the pipeline is accelerating, with a market projected to more than double by 2034.

But behind this promise lies a growing tension:

The science is exponential.

The funding models are not.

The pricing paradox: cures at a million euros

Gene therapies fundamentally challenge traditional pharmaceutical economics.

• Many treatments are one-time interventions with lifelong impact

• Prices range from €300,000 to over €3 million per patient 

• CAR-T and similar therapies can exceed $1 million per patient globally 

This creates a paradox:

The more transformative the therapy, the harder it becomes to finance.

Unlike chronic treatments, gene therapies compress decades of value into a single upfront cost, overwhelming annual healthcare budgets.

Europe’s structural bottleneck: national reimbursement vs central approval

In Europe, the problem is not regulatory approval—it is access.

• Marketing authorization is centralized via the EMA

• Reimbursement decisions remain national

• Health Technology Assessment (HTA) frameworks vary widely

Result:

• Unequal access between countries

• Delayed patient uptake

• Even withdrawal of therapies for commercial reasons 

The upcoming EU HTA regulation (effective 2025) aims to harmonize clinical evaluation—but pricing and funding decisions remain fragmented.

The Benelux reality: advanced systems under pressure

The Benelux region illustrates this tension particularly well:

• The Netherlands uses “coverage lock” mechanisms for expensive therapies

• Belgium faces increasing hospital budget constraints

• Regional collaborations (e.g., BENELUXA) attempt joint negotiation

Yet even in these advanced systems:

• Access remains slow

• Budget impact concerns dominate decisions

• Innovative payment models are still experimental

The scalability problem: from rare diseases to larger populations

Initially, gene therapies targeted ultra-rare diseases.

Today, the focus is expanding to:

• Oncology (CAR-T)

• More prevalent genetic conditions

This shift changes everything:

• Small patient populations → manageable budgets

• Larger populations → exponential cost escalation

Indeed, therapies like CAR-T already generate significant cumulative spending due to higher patient volumes, not just high unit prices.

Innovation meets financial uncertainty

The funding challenge is now impacting the entire ecosystem:

• Venture capital investment in gene therapy has dropped sharply since 2021

• Manufacturing remains complex and costly

• Investors are increasingly cautious

This creates a dangerous loop:

High costs → restricted access → uncertain returns → reduced investment → slower innovation

Access delays cost lives

The consequences are not theoretical.

Across Europe, faster access to CAR-T therapies could:

• Save ~1,200 additional lives across 12 countries

In other words:

The funding problem is becoming a public health problem.

Why traditional models fail

Current reimbursement systems were designed for:

• Chronic treatments

• Predictable outcomes

• Large populations

Gene therapies break all three assumptions:

Traditional model

Gene therapy reality

Pay per dose

Pay once for lifetime

Short-term outcomes

Long-term uncertainty

Large populations

Small or variable populations

This mismatch is the core of the crisis.

Emerging solutions—but not yet scalable

Several models are being explored:

1. Outcome-based payments

Pay only if the therapy works

2. Annuity models

Spread cost over several years

3. Managed Entry Agreements

Conditional reimbursement with data collection

4. Cross-country collaboration

Joint negotiation (e.g., BENELUXA)

However:

• Administrative complexity is high

• Data requirements are heavy

• Long-term outcomes remain uncertain

The uncomfortable truth

Europe is facing a strategic choice:

Either adapt funding models or limit access to breakthrough therapies

Because today:

• Innovation is accelerating

• Budgets are not

And the gap is widening.

What this means for stakeholders

For policymakers

Rethink budget silos and annual accounting logic

For industry

Demonstrate value beyond clinical efficacy (system impact, long-term savings)

For healthcare systems

Shift from cost control to value-based investment

For patients

Access will increasingly depend on geography and system agility

Final perspective

Gene therapy is not just a scientific revolution.

It is a stress test for healthcare systems.

The question is no longer

“Can we cure?”

But:

“Can we afford to cure—at scale?”

References (selection)

• Han Y. Pricing and reimbursement policies and access challenges (2026)

• European Medicines Agency / EuroGCT – HTA & access workshop (2025)

• Alliance for Regenerative Medicine / ISPOR reports on ATMP reimbursement

• COGEM report: The Value of Gene Therapy (2024)

• ASH (2026): global access and cost of CAR-T therapies

• Labiotech (2025): funding challenges in gene therapy

• Tan et al. (2026): impact of faster access to CAR-T

• IHE / EFPIA Cancer Comparator Report Europe (2025)